Unbound MEDLINE

Diffuse large B-cell lymphoma: current strategies and future directions.

Abstract

BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) is the most common histology of non-Hodgkin lymphoma, representing 25% to 35% of new cases annually. The incidence of DLBCL has doubled in the past decades, highlighting the need for more effective treatment regimens.
METHODS
This article reviews the current protocols applicable to this aggressive lymphoma and discusses ongoing research that is focusing on molecular diagnostics, prognostic factors have also been defined for DLBCL.
RESULTS
Patients with DLBCL vary in clinical presentation, prognosis, and response to current therapies. While current therapy in the rituximab era has led to improved outcomes with reduced toxicity, novel treatment approaches for localized, advanced, and relapsed/refractory DLBCL are being pursued in clinical trials. Several studies have shown promise, such as trials involving proteasome inhibitors, lenalidomide, and antibody drug conjugates.
CONCLUSIONS
Recent discoveries in the spectrum of care for patients with DLBCL have prompted a renaissance for personalized cancer medicine and molecularly targeted therapy. Potential targets and novel drug combinations are undergoing continued study in the hope of achieving successful and personalized care of this disease.

Links

  • FREE Publisher Full Text
  • Authors

    Cultrera JL, Dalia SM

    Source

    Cancer control : journal of the Moffitt Cancer Center 19:3 2012 Jul pg 204-13

    MeSH

    Antibodies, Monoclonal, Murine-Derived
    Antineoplastic Agents
    Forecasting
    Humans
    Lymphoma, Large B-Cell, Diffuse

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    22710896